Aveanna Healthcare (AVAH) Stock Forecast and Price Target (2026)

The average target of $13.35 sits roughly in line with the $13.46 price, -0.8%. The median is $14.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

The published targets span $8.00 to $16.00. That gap is 60% of the average target, which counts as moderate disagreement. That is a fairly typical spread: enough agreement that the average means something, enough disagreement that it should not be treated as precise.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the AVAH is it a buy page.

In the last six months there have been 10 raises and 1 cut among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving. Note the tension here: the average target sits below the current price, yet the recent individual actions have mostly been raises. That usually means the published average has not caught up with the most recent revisions, and it is a good reason not to lean on the average alone.

Of the analysts with a published rating, 8 say buy, 3 say hold, and 0 say sell, so 73% carry a buy. That buy share has risen over the last three months, so sentiment is drifting more positive.

Read the distribution rather than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

• It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
• The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
• Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
• Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering AVAH do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

On the figures we hold as of September 2026, AVAH trades at about 10.7 times trailing earnings and 15.0 times forward earnings. A forward multiple at or above the trailing one means the market is not pricing in earnings growth over the next year, which is worth understanding before assuming a long-horizon rise.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Aveanna Healthcare can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are State Medicaid rate increases versus caregiver wages, Preferred payer agreements and government affairs, Consolidating a fragmented pediatric nursing market. The risk cited most often against it is payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the AVAH is it a buy page. This page deliberately stops at the numbers.